Analysts see promise in FibroGen's early Duchenne study — now they want to see a pivotal trial
Apart from Pfizer $PFE, FibroGen $FGEN on Friday also presented early data on its drug for Duchenne muscular dystrophy.
The drug, pamrevlumab, is a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
